Ligand Pharmaceuticals Incorporated
LGNDLigand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
Drugs in Pipeline
11
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
lasofoxifene
Osteoporosis
LGD-6972-5 mg
Type 2 Diabetes Mellitus
MB07803
Type 2 Diabetes Mellitus
Budesonide + Azelastine
Seasonal Allergic Rhinitis
MB07133 300mg/m2/day
Hepatocellular Carcinoma
bexarotene
Breast Cancer
denileukin diftitox
Drug/Agent Toxicity by Tissue/Organ
PS433540
Hypertension
Aplindore
Early Stage Parkinson's Disease
irbesartan
Hypertension
Budesonide
Seasonal Allergic Rhinitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
lasofoxifene | Phase 3 | Osteoporosis | - | - |
LGD-6972-5 mg | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MB07803 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Budesonide + Azelastine | Phase 2 | Seasonal Allergic Rhinitis | - | - |
MB07133 300mg/m2/day | Phase 2 | Hepatocellular Carcinoma | - | - |
bexarotene | Phase 2 | Breast Cancer | - | - |
denileukin diftitox | Phase 2 | Drug/Agent Toxicity by Tissue/Organ | - | - |
PS433540 | Phase 2 | Hypertension | - | - |
Aplindore | Phase 2 | Early Stage Parkinson's Disease | - | - |
irbesartan | Phase 2 | Hypertension | - | - |
Budesonide | Phase 2 | Seasonal Allergic Rhinitis | - | - |